Summary
Eli Lilly and Company's 10-Q filing for the period ending September 29, 1995, indicates a company focused on its core pharmaceutical business. While specific financial figures and operational details are not provided in the excerpt, the filing signifies Lilly's ongoing reporting obligations and engagement with the Securities and Exchange Commission. Investors should look for details on product sales, research and development pipelines, and any significant regulatory or legal developments in the full report to assess the company's performance and future outlook.
Key Highlights
- 1Eli Lilly & Co. (LLY) filed a 10-Q Quarterly Report for the period ending September 29, 1995.
- 2The filing date was November 13, 1995, indicating timely reporting.
- 3The report is an official SEC filing, providing transparency for investors.
- 4This filing is part of routine financial disclosure for publicly traded companies.
- 5Investors can access detailed financial statements and management discussion within the complete 10-Q document.
Frequently Asked Questions
The 10-Q filing is a mandatory quarterly report that publicly traded companies like Eli Lilly & Co. must submit to the Securities and Exchange Commission (SEC). It provides investors with an update on the company's financial performance and condition during the specified quarter.
A full 10-Q report typically includes unaudited financial statements (income statement, balance sheet, cash flow statement), management's discussion and analysis of financial condition and results of operations, details on legal proceedings, and disclosures about any significant changes in internal controls.
The complete filing, including detailed financial data and narrative explanations, can be found on the SEC's EDGAR database. You would search for Eli Lilly & Company (LLY) and the specific filing date or report type (10-Q) for the period ending September 29, 1995.
Based on the provided excerpt, the filing confirms that Eli Lilly & Co. is actively operating and complying with SEC reporting requirements. For specific operational details, such as product sales, R&D updates, or market performance, investors would need to review the full content of the 10-Q report.